AZD0233 + AZD0233 Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dilated Cardiomyopathy
Conditions
Dilated Cardiomyopathy
Trial Timeline
Apr 1, 2024 → Dec 30, 2025
NCT ID
NCT06381466About AZD0233 + AZD0233 Placebo
AZD0233 + AZD0233 Placebo is a phase 1 stage product being developed by AstraZeneca for Dilated Cardiomyopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT06381466. Target conditions include Dilated Cardiomyopathy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06381466 | Phase 1 | Terminated |
Competing Products
10 competing products in Dilated Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin | AstraZeneca | Approved | 85 |
| AZD4063 | AstraZeneca | Phase 1 | 33 |
| ARRY-371797, p38 inhibitor, oral | Pfizer | Phase 2 | 51 |
| ARRY-371797 (PF-07265803) | Pfizer | Phase 3 | 76 |
| ARRY-371797, p38 inhibitor; oral | Pfizer | Phase 2 | 51 |
| danicamtiv | Bristol Myers Squibb | Phase 2 | 51 |
| Ixmyelocel-T | Vericel | Phase 2 | 47 |
| ixmyelocel-T | Vericel | Phase 2 | 47 |
| Ixmyelocel-T | Vericel | Phase 2 | 47 |
| talfirastide | Constant Therapeutics | Phase 2 | 44 |